Thrombus extension after cyanoacrylate closure of incompetent saphenous veins
16
Issued Date
2022-04-01
Resource Type
ISSN
03929590
eISSN
18271839
Scopus ID
2-s2.0-85128245405
Pubmed ID
35005874
Journal Title
International Angiology
Volume
41
Issue
2
Start Page
143
End Page
148
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Angiology Vol.41 No.2 (2022) , 143-148
Suggested Citation
Sermsathanasawadi N., Pruekprasert K., Prapassaro T., Puangpunngam N., Hongku K., Hahtapornsawan S., Chinsakchai K., Wongwanit C., Ruangsetakit C. Thrombus extension after cyanoacrylate closure of incompetent saphenous veins. International Angiology Vol.41 No.2 (2022) , 143-148. 148. doi:10.23736/S0392-9590.22.04768-X Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/85982
Title
Thrombus extension after cyanoacrylate closure of incompetent saphenous veins
Author's Affiliation
Other Contributor(s)
Abstract
Background: Cyanoacrylate closure (CAC) is a minimally invasive surgery to treat incompetent saphenous veins. This study aimed to investigate the incidence, the risk factors for, and the management of thrombus extension after cyanoacrylate closure (TEACAC) of incompetent saphenous veins in patients with chronic venous disease. Methods: This retrospective study included patients aged >18 years who were diagnosed with chronic venous disease with superficial venous reflux in the great saphenous vein, anterior accessory saphenous vein, or small saphenous vein, and who were treated with CAC at Siriraj Hospital (Bangkok, Thailand) during January 2017 to December 2018. Results: A total of 126 saphenous veins of 101 patients were included. TEACAC occurred in 5 of 101 (4.9%) patients, and in 5 of 126 (3.9%) treated saphenous veins. The mean follow-up time was 285±12 days. Based on Kabnick classification of endovenous heat-induced thrombosis (EHIT), the following TEACAC grades were observed: grade I (N.=2), grade II (N.=1), grade III (N.=2), and grade IV (N.=0). No patient or procedural predictive factors for TEACAC were identified. In patients with TEACAC-1 or TEACAC-2, the thrombus spontaneously disappeared by the 2-week follow-up. Patients with TEACAC-3 received therapeutic rivaroxaban or dabigatran, which resolved the thrombus within 2-4 weeks. No deep vein thrombosis or symptomatic pulmonary embolism was found. Conclusions: TEACAC was found not to be a rare complication after CAC. All patients should be informed of the risk of TEACAC prior to treatment. Treatment of TEACAC class 1-3 following EHIT guideline seems to be both safe and effective.